
Prostate Health Market Report and Forecast 2025-2034
Description
The global prostate health market size was valued at USD 38.10 Billion in 2024, driven by the increasing incidence of prostate cancer across the globe. The market size is anticipated to grow at a CAGR of 9.10% during the forecast period of 2025-2034 to achieve a value of USD 91.03 Billion by 2034.
Prostate Health: Introduction
The prostate is a small, rubbery gland in the male reproductive system. It is located in the pelvis, below the bladder and in front of the rectum. It is about the size of a walnut and weighs about 11 grams. The prostate's primary function is to produce the fluid that nourishes and transports sperm. This fluid, called seminal fluid, mixes with sperm from the testes to make semen. Prostate's muscles also help push semen through the urethra.
Prostate health refers to the well-being and proper functioning of the prostate gland, which is a small, walnut-sized organ located just below the bladder in men. The prostate gland plays a crucial role in the male reproductive system by producing seminal fluid, which nourishes and transports sperm during ejaculation.
Global Prostate Health Market Analysis
The growth of the global market for prostate health is driven by the increasing numbers of FDA approvals for new drugs targeted at addressing various aspects of prostate health. For example, approval of the fixed-dose combination of niraparib and abiraterone acetate for patients with certain types of prostate cancer, offering new treatment options is a major step and hope for new and effective treatment for prostate cancers. The market is also driven by the heavy investments by the leading key players. Increasing investments and funding in prostate health research and treatment innovations are also market trends influencing the global prostate health market growth. Researchers have been exploring novel therapies that show promising results in treating prostate cancer, even in cases where existing treatments have proven ineffective. These innovations bring hope to those patients who are suffering from the disease and offer potential innovation in prostate cancer management. Increasing efforts to reduce harm from prostate cancer screening are also accountable for the market growth.
Additionally, strategic mergers and acquisitions among key players in the healthcare industry are also contributing to the market growth. Collaborative efforts, such as the merger between Pfizer Inc. and Seagen Inc., demonstrate a concerted effort to combat cancer and develop transformative therapies. These partnerships are expected to further propel the prostate health market growth.
Global Prostate Health Market Segmentations
“global prostate health market and forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market by Treatment Type Radical Prostatectomy
Orchidectomy
Trans Urethral Resection
Others
The growth of global prostate health market growth is driven by several key factors including prostate cancer being the second most common cancer in men worldwide, highlighting the quick need for effective treatments and diagnostics. The growing prevalence of benign prostatic hyperplasia (BPH), a common condition among aging men, further contributes to the market's expansion. The increasing geriatric population acts as a major factor driving the market growth as well. The emergence of new treatment therapies and techniques for prostate cancer holds promise in improving patient outcomes and potential to drive market growth. Rapid growth in the availability of biomarker testing, allowing for early detection and more precise treatment decisions also collectively accountable for the market growth. Investments in research and development, coupled with a surge in upcoming pipeline medicines and the availability of innovative prostate treatments, are propelling the global prostate health market growth.
Geographically, North America is leading the regional market for prostate health, and it is expected to lead the market for the forecast period as well. The prevalence of prostate diseases, including prostate cancer in the region is also increasing, which is driving the market growth. The increased investment in research and development, the promising pipeline of medicines, and the availability of novel prostate health solutions collectively contribute to the market growth.
Global Prostate Health Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Prostate Health: Introduction
The prostate is a small, rubbery gland in the male reproductive system. It is located in the pelvis, below the bladder and in front of the rectum. It is about the size of a walnut and weighs about 11 grams. The prostate's primary function is to produce the fluid that nourishes and transports sperm. This fluid, called seminal fluid, mixes with sperm from the testes to make semen. Prostate's muscles also help push semen through the urethra.
Prostate health refers to the well-being and proper functioning of the prostate gland, which is a small, walnut-sized organ located just below the bladder in men. The prostate gland plays a crucial role in the male reproductive system by producing seminal fluid, which nourishes and transports sperm during ejaculation.
Global Prostate Health Market Analysis
The growth of the global market for prostate health is driven by the increasing numbers of FDA approvals for new drugs targeted at addressing various aspects of prostate health. For example, approval of the fixed-dose combination of niraparib and abiraterone acetate for patients with certain types of prostate cancer, offering new treatment options is a major step and hope for new and effective treatment for prostate cancers. The market is also driven by the heavy investments by the leading key players. Increasing investments and funding in prostate health research and treatment innovations are also market trends influencing the global prostate health market growth. Researchers have been exploring novel therapies that show promising results in treating prostate cancer, even in cases where existing treatments have proven ineffective. These innovations bring hope to those patients who are suffering from the disease and offer potential innovation in prostate cancer management. Increasing efforts to reduce harm from prostate cancer screening are also accountable for the market growth.
Additionally, strategic mergers and acquisitions among key players in the healthcare industry are also contributing to the market growth. Collaborative efforts, such as the merger between Pfizer Inc. and Seagen Inc., demonstrate a concerted effort to combat cancer and develop transformative therapies. These partnerships are expected to further propel the prostate health market growth.
Global Prostate Health Market Segmentations
“global prostate health market and forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market by Treatment Type
- Hormonal Therapy
- Chemotherapy
- Surgical Treatments
- Other Treatment Types
- Benign Prostatic Hyperplasia (BPH)
- Prostatitis
- Prostate Cancer
- Others
- Adults
- Geriatrics
- Others
- Hospitals and Clinics
- Speciality Clinics
- Homecare Settings
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The growth of global prostate health market growth is driven by several key factors including prostate cancer being the second most common cancer in men worldwide, highlighting the quick need for effective treatments and diagnostics. The growing prevalence of benign prostatic hyperplasia (BPH), a common condition among aging men, further contributes to the market's expansion. The increasing geriatric population acts as a major factor driving the market growth as well. The emergence of new treatment therapies and techniques for prostate cancer holds promise in improving patient outcomes and potential to drive market growth. Rapid growth in the availability of biomarker testing, allowing for early detection and more precise treatment decisions also collectively accountable for the market growth. Investments in research and development, coupled with a surge in upcoming pipeline medicines and the availability of innovative prostate treatments, are propelling the global prostate health market growth.
Geographically, North America is leading the regional market for prostate health, and it is expected to lead the market for the forecast period as well. The prevalence of prostate diseases, including prostate cancer in the region is also increasing, which is driving the market growth. The increased investment in research and development, the promising pipeline of medicines, and the availability of novel prostate health solutions collectively contribute to the market growth.
Global Prostate Health Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott
- Novartis AG
- Teleflex
- AstraZeneca PLC
- Bayer AG
- Sanofi
- Pfizer
- Clovis Oncology
- Siemens Healthcare GmbH
- Elekta
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Prostate Health Market Overview
- 3.1 Global Prostate Health Market Historical Value (2018-2024)
- 3.2 Global Prostate Health Market Forecast Value (2025-2034)
- 4 Global Prostate Health Market Landscape
- 4.1 Global Prostate Health Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Prostate Health Product Landscape
- 4.2.1 Analysis by Treatment
- 4.2.2 Analysis by Indications
- 4.2.3 Analysis by Age Group
- 5 Global Prostate Health Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Prostate Health Market Segmentation
- 6.1 Global Prostate Health Market by Treatment Type
- 6.1.1 Market Overview
- 6.1.2 Hormonal Therapy
- 6.1.3 Chemotherapy
- 6.1.4 Surgical Treatments
- 6.1.4.1 Radical Prostatectomy
- 6.1.4.2 Orchidectomy
- 6.1.4.3 Trans Urethral Resection
- 6.1.4.4 Others
- 6.1.5 Other Treatment Types
- 6.2 Global Prostate Health Market by Indications
- 6.2.1 Market Overview
- 6.2.2 Benign Prostatic Hyperplasia (BPH)
- 6.2.3 Prostatitis
- 6.2.4 Prostate Cancer
- 6.2.5 Others
- 6.3 Global Prostate Health Market by Age Group
- 6.3.1 Market Overview
- 6.3.2 Adults
- 6.3.3 Geriatrics
- 6.3.4 Others
- 6.4 Global Prostate Health Market by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals and Clinics
- 6.4.3 Speciality Clinics
- 6.4.4 Homecare Settings
- 6.4.5 Others
- 6.5 Global Prostate Health Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Prostate Health Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Prostate Health Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Prostate Health Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Prostate Health Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Prostate Health Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 Abbott
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisition
- 17.1.5 Certifications
- 17.2 Novartis AG
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisition
- 17.2.5 Certifications
- 17.3 Teleflex
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisition
- 17.3.5 Certifications
- 17.4 AstraZeneca PLC
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisition
- 17.4.5 Certifications
- 17.5 Bayer AG
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisition
- 17.5.5 Certifications
- 17.6 Sanofi
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisition
- 17.6.5 Certifications
- 17.7 Pfizer
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Clovis Oncology
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Siemens Healthcare GmbH
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisition
- 17.9.5 Certifications
- 17.10 Elekta
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisition
- 17.10.5 Certifications
- 18 Global Prostate Health Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.